Table 1.
Demographic data and baseline characteristics of the patients (n = 371)
| Item | Data |
|---|---|
| Age (years) | 49.9 ± 18.7 |
| Gender (female %) | 112 (30%) |
| BMI (kg/m2) | |
| ≤ 18 | 26 (7%) |
| 18–25 | 226 (61%) |
| ≥ 25 | 119 (32%) |
| Intervertebral disc level | |
| L1/2 | 8 (2%) |
| L2/3 | 15 (4%) |
| L3/4 | 19 (5%) |
| L4/5 | 185 (50%) |
| L5/S1 | 144 (39%) |
| Symptom duration before injection (months) | 7.1 ± 5.8 |
| Follow-up period (months) | 13.1 ± 7.4 |
| Baseline Pfirrmann grade | |
| Grade II | 15 (4%) |
| Grade III | 181 (49%) |
| Grade IV | 157 (42%) |
| Grade V | 18 (5%) |
| High-intensity MRI signal in herniation | 70 (19%) |
| Classification of herniation | |
| Subligamentous | 234 (63%) |
| Transligamentous | 137 (37%) |
| Injection into central region of disc | 341 (92%) |
| Baseline VAS leg pain | 7.1 ± 1.8 |
| Bulging ratio of herniation (%) | 29.1 ± 10.7 |
| Reduction rate of herniated mass volume (%) | 31.2 ± 17.4 |
| ≥ 50% decrease of herniated mass volume (n) | 96 (26%) |
Continuous data are presented as mean ± standard deviation